Humira injection. Close-up of the mark left of a patient's skin after self-injecting a dose of the drug adalimumab, marketed under the name Humira. Adalimumab is a human monoclonal antibody that targets excess tumour necrosis factor (TNF) in the body, overproduction of which causes inflammation, swelling, and pain. It is used for the treatment of autoimmune diseases such as rheumatoid and psoriatic arthritis, Crohn's disease and ulcerative colitis.
Model release available. Property release not available.